After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
GlobalData on MSN7h
Novartis strengthens radiopharma leadership with Ratio Therapeutics dealNovartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback